Research & Markets: Competitor Analysis: Antibody-Drug Conjugates (ADC)

December 2011
Biomedical Market Newsletter;12/14/2011, Vol. 21, p1
The article focuses on the "Competitor Analysis: Antibody-Drug Conjugates (ADC)" report released from Research & Markets Ltd. The report provides information on the current projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology including drug codes, mechanism of action and class of compound. The companies mentioned in the report include Ambrx Amgen, Centrose Cytoguide and GlaxoSmithKline.


Related Articles

  • Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Xu, Shi // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3577 

    Purpose: This review discusses the molecular mechanism involved in the targeting and delivery of antibody-drug conjugates (ADCs), the new class of biopharmaceuticals mainly designed for targeted cancer therapy. Methods: this review goes over major progress in preclinical and clinical studies of...

  • A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. Vasalou, Christina; Helmlinger, Gabriel; Gomes, Bruce // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading...

  • Wacker honors Alber and Kunert with innovation award.  // Rubber World;Aug2011, Vol. 244 Issue 5, p12 

    The article announces that researchers Anne Alber and Jan Kunert have received the Alexander Wacker Innovation Award.

  • Conjugal Bliss? Another Partner Favors SeaGen Approach: GSK. Osborne, Randy // BioWorld Today;12/22/2009, Vol. 20 Issue 245, p1 

    The article reports on a deal signed by Seattle Genetics Inc. with GlaxoSmithKline plc (GSK). Under the deal, GSK will pay 12 million U.S. dollar up front and 390 million U.S. dollar in milestone payments, for the research, product development, manufacturing and commercialization of the...

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer. Shaffer, Catherine // BioWorld Today;1/7/2011, Vol. 22 Issue 5, p1 

    The article reports on a licensing deal signed by Pfizer Inc. with Seattle Genetics Inc. (Seagen) for access to Seattle's antibody-drug conjugate (ADC). The 200 million dollar deal was reportedly closed at a significant premium over a similar deal with GlaxoSmithKline plc in December 2009. It...

  • Seattle Genetics enters into collaboration with GSK for antibody drug.  // PharmaWatch: Biotechnology;Feb2010, Vol. 9 Issue 2, p16 

    The article reports on the collaboration agreement entered between Seattle Genetics Inc. and GlaxoSmithKline (GSK) on the development of the antibody-drug (ADC) conjugate in the U.S. The agreement stipulates the need for GSK to pay 12 million U.S. dollar upfront fee for the right to utilize the...

  • GSK nabs speedy review for one of its top prospects. Adams, Ben // FierceBiotech;1/21/2020, pN.PAG 

    With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

  • Merck & Co. Forays into Biologic-Drug Conjugates in Collaboration with Ambrx. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 6, p92 

    Ambrx has formed a collaboration with Merck & Co., potentially worth US$303 M, to develop biologic-drug conjugates directed at multiple prespecified targets using its EuCODEâ„¢ site-specific protein medicinal chemistry technology platform. Unlike other industry alliances for the development...

  • Evaluating the Bioequivalence of Antibody-Drug Conjugates. Breau, Alan; Whitmire, Monica // Pharmaceutical Technology;Nov2011 Supplement, ps22 

    The article discusses the importance of the antibody-drug conjugates (ADCs) for the development of drugs particularly for oncology in the U.S. It states that the combination of monoclonal antibody (mAb) and cytotoxin results to the formation of ADC that maintains recognition of the target after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics